Iovance Biotherapeutics, Inc.
825 Industrial Rd
Suite 400
San Carlos
California
94070
United States
Website: http://www.iovance.com/
294 articles about Iovance Biotherapeutics, Inc.
-
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences - Jan 19, 2021
1/19/2021
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following virtual healthcare conferences
-
Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
12/28/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Maria Fardis, PhD, MBA, President and Chief Executive Officer of Iovance, plans to present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021, at 10:50 a.m. ET. The live and archived webcasts of the presentation and breakout session will be available in th
-
Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer
12/14/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Jean-Marc Bellemin as Chief Financial Officer, effective today. Mr. Bellemin brings 27 years of industry experience in finance, including public companies. “I am very pleased to welcome Jean-Marc to Iovance during such an important time for the Company,” stated Maria Fard
-
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
-
Iovance Biotherapeutics to Present at Upcoming Conferences in December
11/30/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November: Piper Sandler 32nd Annual Virtual Healthcare Conference | December 1-3, 2020 Date/Time: presentation available at http://ir.iovance.com Cellular Immunotherapies for Solid Tumors Summit | December 1-
-
Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
11/9/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today presented new interim clinical data for the tumor infiltrating lymphocyte (TIL) therapy LN-145
-
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate UpdatesRegistration-Directed Study Initiated in Non-Small Cell Lung Cancer
11/5/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported third quarter 2020 financial results and provided a corporate update.
-
Iovance Biotherapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5, 2020
10/30/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter 2020 financial results on Thursday, Nov. 5, 2020.
-
Iovance Biotherapeutics to Present at Upcoming Conferences in November
10/28/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November: Next Generation CAR and T Cell Therapies Conference (Virtual) | Nov . 2-5, 2020 Date/Time: Monday, Nov. 2 at 5:20 p.m. EST Credit Suisse 29th Annual Virtual Healthcare Conference | Nov . 9-12, 2
-
Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
10/14/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), today announced that new interim clinical data for the tumor infiltrating lymphocyte (TIL) therapy LN-145 in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC) will be presented at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
-
Iovance Biotherapeutics to Present at Upcoming October 2020 Conferences
10/6/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that the company plans to present at the following conferences.
-
Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
10/5/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma
-
Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020
8/7/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the BTIG Biotechnology Conference 2020 (Virtual) on August 11, 2020 at 2:30pm ET. A live and archived webcast of the presentation will be available in the Investors section of the Iovance website at http://ir.iovance.com . About Iovance Biotherapeut
-
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate UpdateEnrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study
8/6/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported second quarter 2020 financial results and provided a corporate update.
-
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001
8/6/2020
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Iovance Biotherapeutics (NASDAQ: IOVA) has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services t
-
Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
7/23/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT. To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-24
-
Iovance Biotherapeutics to Present at Upcoming June Conferences
6/8/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following virtual conferences in June
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
DLA Piper advises Iovance Biotherapeutics in its US$604 million common stock offering
6/4/2020
DLA Piper represented Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), in a US$603.7 million underwritten public offering of 19,475,806 shares of its common stock at a public offering price of $31.00 per share,
-
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public OfferingOffering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 2.5 Million Shares of Common Stock
6/2/2020
Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the closing of an underwritten public offering of 19,475,806 shares of its common stock at a public offering price of $31.00 per share.